VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
PRE
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
PREPrenetics Global Limited
$22.71$386M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
PRE logo

Prenetics Global Limited

PRE
NASDAQ · Diagnostics & Research
$22.71
At close - Sep 23, 4:00 PM EDT - USD
Market Cap$386M
P/E-8.5x
52W High$27.24
Volume245.77K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Rapid Revenue Scaling Faces Severe Profitability Headwinds

Prenetics is currently navigating a high-stakes transition from legacy pandemic testing to specialized clinical diagnostics, evidenced by a 107.7% year-over-year revenue growth in 2026Q1. While the company has successfully improved gross margins to 64.8%, the ...

GrowthAccelerating
ProfitabilityNegative
ValuationReview
TechnicalsHealthy
Explore valuation models
MARKET ACTION

PRE price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

4/12 Beats

EPS beat 4 of last 12 quarters

02

Valuation risk

-122% Peers

P/E is 122% below peer median

03

Market leadership

RS 90 · Leader

High momentum (Outperforming 90% of market)

04

Healthy Uptrend

Uptrend

Price > 50DMA > 200DMA

Next CatalystConfirmed earnings · Nov 9

Market performance

Price History →

Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
PRE+43.92%
S&P 500 (^GSPC)+12.39%
1-Year Return
PRE+83.29%
S&P 500 (^GSPC)+15.77%
3-Year Return
PRE+229.13%
S&P 500 (^GSPC)+83.94%
5-Year Return
PRE-80.33%
S&P 500 (^GSPC)+71.64%

Growth & profitability

Annual revenue & EPS trend
Revenue
$92M+201.7% YoY
Net income
-$38M+18.6% YoY
Free cash flow
-$22M+26.5% YoY
Operating margin
-41.3%+116.0 pts YoY
ROIC (TTM)-21.2%
Avg ROIC 5Y-
ROE (TTM)-21.8%
Piotroski Score6 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate4/12 (36%)
Revenue Beat Rate3/12 (27%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q3 2026Latest
Aug 18, 2026
-$0.53+36.9%
vs -$0.84
$46M-6.7%
vs $50M
Q3 2026
Jun 10, 2026
-$1.36-177.6%
vs -$0.49
$36M-0.1%
vs $36M
Q2 2026
May 14, 2026
-$1.14-131.6%
vs -$0.49
$36M-2.3%
vs $37M
Q1 2026
Feb 18, 2026
-$1.75-326.8%
vs -$0.41
$37M+9.5%
vs $33M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

5 Stories
GlobeNewsWire·Aug 26, 2026
Prenetics' IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results

Cumulative Personal Investment by Leadership Since November 2025 Reaches Approximately $3.75 Million NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading consumer health company and parent of the AI-native direct-to-consumer wellness brand IM8, co-founded by David Beckham, today announced that Danny Yeung, Chief Executive Officer, and Brian Rosin, Chief Financial Officer, completed open market purchases of the Company's ordinary shares during the period between August 20 and August 25, 2026, within the Company's open trading window following the release of second quarter 2026 financial results. The two executives acquired $1.0 million of shares.

Seeking Alpha·Aug 24, 2026
Prenetics Global: Marketing Mastery The Key To Robust Revenue Growth

Prenetics Global Limited has achieved explosive growth, reaching 140,000 subscriptions in 20 months, driven by its IM8 supplement and AI-powered marketing. One of the keys to this growth is its marketing mastery, using A/B and multivariate testing to quickly identify the most effective advertising messages. A unique deal with General Catalyst enables PRE to finance up to 70% of customer acquisition costs without equity dilution or debt, amplifying marketing leverage.

Seeking Alpha·Aug 22, 2026
Prenetics Global Limited (PRE) Q2 2026 Earnings Call Transcript

Prenetics Global Limited (PRE) Q2 2026 Earnings Call Transcript

GlobeNewsWire·Aug 20, 2026
Prenetics' IM8 Announces Two-Time Golden Globe-Nominated Actress and Producer Lily Collins as IM8 Global Ambassador and Shareholder in Multi-Year Partnership

— Lily is IM8's first Global Ambassador from film and television, extending a roster built in elite sport into global entertainment and culture — Lily brings a following of more than 33 million across social platforms and an engagement rate of approximately 5.9%, several times the benchmark for accounts of comparable scale — Partnership lands as Prenetics raises FY 2026 revenue guidance to $220+ million; Initiates FY 2027 revenue guidance of $400+ million — Joins an equity-aligned roster of David Beckham, Giannis Antetokounmpo, Aryna Sabalenka, Ollie Bearman, Jay Shetty and Inter Miami CF NEW YORK, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), the parent company of IM8, the premium health and longevity brand co-founded with David Beckham, today announced a multi-year global partnership with two-time Golden Globe-nominated actress and producer Lily Collins, star and executive producer of Netflix's Emily in Paris. Collins becomes a Global Ambassador of IM8 and a shareholder in Prenetics, demonstrating her long-term conviction in the brand and the Company.

Filtered for Prenetics Global LimitedMore Headlines
04

Compare before deciding

Benchmark PRE against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Prenetics Global Limited (PRE)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
PRE logoPREPrenetics Global LimitedCurrent
$22.71$386.08M-8.47201.72%-40.81%-21.81%—
EXAS logoEXASExact Sciences Corporation
$104.91$20.02B-95.3717.69%-6.4%-8.66%—
NTRA logoNTRANatera, Inc.
$390.79$55.97B-257.1035.9%-7.11%-11.73%—
CSTL logoCSTLCastle Biosciences, Inc.
$34.88$1.06B-42.023.66%-5.43%-4.15%—
QDEL logoQDELQuidelOrtho Corporation
$10.34$705.09M-0.62-1.89%-39.2%-55.3%—
AHCO logoAHCOAdaptHealth Corp.
$5.70$775.51M-10.96-0.49%-7.58%-15.08%—

Compare PRE vs Peers

Prenetics Global Limited (PRE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs EXAS

Most directly comparable listed peer for PRE.

Scale Benchmark

vs TMO

Larger-name benchmark to compare PRE against a more recognizable public peer.

Peer Set

Compare Top 5

vs EXAS, NTRA, CSTL, QDEL

Get notified when PRE posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

PRE Frequently Asked Questions

Prenetics Global Limited (PRE) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Prenetics Global Limited's revenue?

Prenetics Global Limited (PRE) reported $142.6M in revenue for fiscal year 2025. This represents a 1444% increase from $9.2M in 2019.

How fast is Prenetics Global Limited growing?

Prenetics Global Limited (PRE) grew revenue by 201.7% over the past year. This is strong growth.

Is PRE profitable?

Prenetics Global Limited (PRE) reported a net loss of $67.6M for fiscal year 2025.

Dividend & Returns
What is PRE's return on equity?

Prenetics Global Limited (PRE) has a return on equity (ROE) of -21.8%. Negative ROE indicates the company is unprofitable.

What is Prenetics Global Limited's free cash flow?

Prenetics Global Limited (PRE) had negative free cash flow of $34.1M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in PRE back in 2019?

Total return calculator · dividends reinvested · 7+ years of data

See returns →